Tricyclic 1,2,4-triazine oxides and compositions for therapeutic use in cancer treatments
申请人:Auckland Uniservices Limited
公开号:US07989451B2
公开(公告)日:2011-08-02
The invention relates to novel tricyclic 1,2,4-triazine-1-oxides and novel tricyclic 1,2,4-triazine-1,4-dioxides of formula I
and to related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.
Tricyclic 1,2,4-Triazine Oxides and Compositions for Therapeutic Use in Cancer Treatments
申请人:Hay Michael Patrick
公开号:US20090186886A1
公开(公告)日:2009-07-23
The invention relates to novel tricyclic 1,2,4-triazine-1-oxides and novel tricyclic 1,2,4-triazine-1,4-dioxides of formula I
and to related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.
TRICYCLIC 1,2,4-TRIAZINE OXIDES AND COMPOSITIONS THEREFROM FOR THERAPEUTIC USE IN CANCER TREATMENTS
申请人:AUCKLAND UNISERVICES LIMITED
公开号:EP1866292B1
公开(公告)日:2010-12-15
US7989451B2
申请人:——
公开号:US7989451B2
公开(公告)日:2011-08-02
[EN] TRICYCLIC 1,2,4-TRIAZINE OXIDES AND COMPOSITIONS THEREFROM FOR THERAPEUTIC USE IN CANCER TREATMENTS<br/>[FR] OXYDES DE 1,2,4-TRIAZINE TRICYCLIQUES ET LEURS COMPOSITIONS A USAGE THERAPEUTIQUE DANS LES TRAITEMENTS ANTICANCEREUX
申请人:AUCKLAND UNISERVICES LTD
公开号:WO2006104406A1
公开(公告)日:2006-10-05
[EN] The invention relates to novel tricyclic 1,2,4-triazine-1-oxides and novel tricyclic 1,2,4-triazine-1,4-dioxides of formula: (I); and to related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs. [FR] La présente invention se rapporte à des 1-oxydes de 1,2,4-triazine tricycliques innovants et à des 1,4-dioxydes de 1,2,4-triazine tricycliques innovants de formule : (I), ainsi qu'aux analogues apparentés. Elle se rapporte également à leur préparation et à leur utilisation en tant que médicaments sélectifs de l'hypoxie et que radiosensibilisants destinés au traitement du cancer, seuls ou en combinaison avec une radiothérapie et/ou d'autres médicaments anticancéreux.